Metastatic malignant cylindroma arising on a background of digenic inheritance of BRCA2 and CYLD pathogenic variants targeted with PARP inhibition
Clinical and Experimental Dermatology · 2025
DOI: 10.1093/ced/llaf064 ↗Kurz gefasst
Fallbericht in der Zeitschrift Clinical and Experimental Dermatology, 2025. Verfasst von William Fostier und 9 weiteren Autor:innen. Beteiligte Einrichtung: Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, UK. Hauptthemen laut MEDLINE: Deubiquitinating Enzyme CYLD, Skin Neoplasms, Carcinoma, Adenoid Cystic, BRCA2 Protein. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Newcastle NIHR Biomedical Research Centre, National Institute of Health Research, NIHR Cambridge Biomedical Research Centre.
Abstract (Originalsprache)
Background
CYLD cutaneous syndrome (CCS) is caused by germline heterozygous pathogenic variants in CYLD and results in the progressive formation of cylindromas, spiradenomas or trichoepitheliomas. Malignant cylindroma is a rare skin adnexal tumour occurring in CCS, which can metastasize with lethal outcomes and has limited genomic characterization. BRCA2 loss in CCS is not described and may modulate the cutaneous cancer risk of CCS.
Objectives
To establish whether BRCA deficiency drives metastatic malignant cylindroma and to report the phenotype of three siblings with digenic inheritance of CYLD and BRCA2 pathogenic variants (PVs), one of whom developed metastatic cylindroma at 28 years old.
Methods
A kindred study reporting seven members of a family with CCS was conducted in a tertiary hospital setting within the United Kingdom from April 2021 to February 2023. Clinical phenotype, pathological, radiological and genetic findings and treatment data were collected. Whole-genome sequencing of the primary malignant cylindroma occurring in one patient was performed to identify targetable driver mutations and signatures.
Results
Malignant cylindroma arose in one (proband) of the two male siblings with digenic inheritance of BRCA2 (c.5158insT) and CYLD (c.2689-2A>G) pathogenic variants. A further female sibling with digenic inheritance of the same BRCA2 and CYLD PVs developed early breast cancer. Whole-genome sequencing of the primary malignant cylindroma in the affected patient showed loss of heterozygosity of both BRCA2 and CYLD. Bioinformatic analysis confirmed homologous repair deficiency (HRD). These data supported the use of the PARP [poly(ADP-ribose) polymerase] inhibitor rucaparib to target HRD in a non-canonical BRCA-deficient skin cancer.
Conclusions
Digenic inheritance of pathogenic variants in cancer-predisposing genes should prompt clinicians to be vigilant for atypical malignant presentations. We demonstrate that rapid whole-genome sequencing can inform the treatment of metastatic malignant cylindroma and identify novel systemic therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, UK.
- Department of Dermatology, Royal Victoria Infirmary, Newcastle upon Tyne, UK.
- Department of Pathology, Royal Victoria Infirmary, Newcastle upon Tyne, UK.
- Department of Oncology, Leeds Teaching Hospital, Leeds, UK.
- Department of Pathology, Leeds Teaching Hospital, Leeds, UK.
- Academic Department of Medical Genetics, University of Cambridge, Cambridge, UK.
ORCID-Profile: William Fostier, Neil Rajan
Förderung
- Newcastle NIHR Biomedical Research Centre
- National Institute of Health Research
- NIHR Cambridge Biomedical Research Centre
- Department of Health and Social Care
Zitieren
APA
Fostier, W., Husain, A., Namini, S., Mathew, B., Holt, G., Memari, Y., Davies, H., Koh, G. C. C., Nik-Zainal, S., & Rajan, N. (2025). Metastatic malignant cylindroma arising on a background of digenic inheritance of BRCA2 and CYLD pathogenic variants targeted with PARP inhibition. Clinical and Experimental Dermatology. https://doi.org/10.1093/ced/llaf064
Vancouver
Fostier W, Husain A, Namini S, Mathew B, Holt G, Memari Y, et al. Metastatic malignant cylindroma arising on a background of digenic inheritance of BRCA2 and CYLD pathogenic variants targeted with PARP inhibition. Clinical and Experimental Dermatology. 2025. doi:10.1093/ced/llaf064
BibTeX
@article{Fostier2025,
author = {Fostier, William and Husain, Akhtar and Namini, Shirin and Mathew, Bipin and Holt, Georgie and Memari, Yasin and Davies, Helen and Koh, Gene C C and Nik-Zainal, Serena and Rajan, Neil},
title = {Metastatic malignant cylindroma arising on a background of digenic inheritance of BRCA2 and CYLD pathogenic variants targeted with PARP inhibition},
journal = {Clinical and Experimental Dermatology},
year = {2025},
doi = {10.1093/ced/llaf064}
}
EUVIMED